Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
- Conditions
- Cervical Cancer
- Registration Number
- NCT00462397
- Lead Sponsor
- University College London Hospitals
- Brief Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, carboplatin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with radiation therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving paclitaxel together with carboplatin followed by cisplatin and radiation therapy works in treating patients with stage IB, stage II, stage III, or stage IVA cervical cancer.
- Detailed Description
OBJECTIVES:
Primary
* Determine the response rate, in terms of clinical or radiologic response at 12 weeks after completion of study therapy, in patients with stage IB2-IVA cervical cancer treated with neoadjuvant chemotherapy comprising dose-dense paclitaxel and carboplatin followed by radical chemoradiotherapy comprising concurrent cisplatin and radiotherapy.
Secondary
* Determine the response rate in patients treated with this neoadjuvant chemotherapy regimen.
* Determine the toxicity of this neoadjuvant chemotherapy regimen in these patients.
* Assess the progression-free survival of patients treated with this regimen.
* Determine the overall survival of patients treated with this regimen.
OUTLINE: This is a multicenter study.
* Neoadjuvant chemotherapy: Patients receive neoadjuvant chemotherapy comprising paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Treatment repeats weekly for up to 6 courses in the absence of disease progression or unacceptable toxicity.
* Chemoradiotherapy: Beginning in week 7, or as soon as blood counts recover, patients receive cisplatin IV over 1 hour on day 1. Treatment repeats weekly for 4-6 courses in the absence of disease progression or unacceptable toxicity. Patients also undergo concurrent radiotherapy comprising pelvic external beam radiotherapy once daily for 5½ weeks (5 weeks for patients with positive para-aortic lymph nodes) and 2 applications of high-dose rate intracavitary brachytherapy or low- or medium-dose rate brachytherapy. Patients with parametrial or pelvic sidewall disease extension also undergo external boost radiotherapy for 3 days.
After completion of study therapy, patients are followed periodically for 2 years.
PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 50
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate at the end of chemoradiotherapy (i.e., 12 weeks after completion of study therapy)
- Secondary Outcome Measures
Name Time Method Overall survival Response rate at the end of neoadjuvant treatment (i.e., 6 weeks after study entry) Toxicity as assessed by NCI CTCAE v3.0 Progression-free survival
Trial Locations
- Locations (3)
Leicester Royal Infirmary
🇬🇧Leicester, England, United Kingdom
Royal Marsden - London
🇬🇧London, England, United Kingdom
University College of London Hospitals
🇬🇧London, England, United Kingdom